Modulation of biomarkers of angiogenesis during treatment with SU11248 (sunitinib malate) in patients with advanced malignancies

被引：0
|
作者：
Deprimo, Samuel E.
Toner, Guy
Mitchell, Paul
De Boer, Richard
Gibbs, Peter
Hicks, Rodney
McArthur, Grant
Brega, Nicoletta
McCarthy, Timothy
Bello, Carlo
机构：
[1] Pfizer Global R&D, La Jolla, CA USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Austin Hosp, Melbourne, Vic, Australia
[4] Royal Melbourne Hosp, Melbourne, Vic, Australia
[5] Pfizer Srl, Milan, Italy
[6] Pfizer Inc, Groton, CT 06340 USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2910
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials
    Motzer, R.
    Rini, B.
    Michaelson, M.
    Redman, B.
    Hudes, G.
    Wilding, I.
    Bukowski, R.
    George, D.
    Kim, S.
    Baum, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 227 - 227
  • [22] FIDG-PET imaging demonstrates kinase target inhibition by sunitinib malate (SU11248) in GIST patients resistant to or intolerant of imatinib mesylate
    Van den Abbeele, A. D.
    Melenevsky, Y.
    de Vries, D.
    Manola, J.
    Dileo, P.
    Tetrault, R.
    Baum, C.
    Badawi, R. D.
    Demetri, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 202 - 203
  • [23] Thyroid dysfunction in patients treated with Sunitinib (SU11248) -: A single center retrospective and prospective evaluation
    Wolter, Pascal
    Wildiers, Hans
    Prenen, Hans
    Bex, Marie
    Dumez, Herlinde
    Schoffski, Patrick
    ANNALS OF ONCOLOGY, 2006, 17 : 136 - 136
  • [24] Phase II study of SU11248 inpatients with advanced malignancies incorporating PET imaging.
    Toner, GC
    Mitchell, PL
    De Boer, R
    Gibbs, P
    Hicks, R
    Scott, AM
    McArthur, G
    Brega, N
    Massimini, G
    McCarthy, T
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6143S - 6143S
  • [25] Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: a pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy
    Davis, D. W.
    Heymach, J. V.
    McConkey, D. J.
    Desai, J.
    George, S.
    Jackson, J.
    Bello, C. D.
    Baum, C.
    Shalinsky, D. R.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2005, 3 (02): : 203 - 203
  • [26] A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
    Rosen, Lee S.
    Bello, Carlo L.
    Mulay, Marilyn
    Dinolfo, Melissa
    Baum, Charles
    CANCER RESEARCH, 2006, 66 (08)
  • [27] Receptor tyrosine kinase activity and apoptosis in gastrointestinal stromal tumours: A pharmacodynamic analysis of response to sunitinib malate (SU11248) therapy.
    Davis, D
    Heymach, J
    McConkey, D
    Desai, J
    George, S
    Jackson, J
    Bello, C
    Baum, C
    Shalinsky, D
    Demetri, G
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9027S - 9027S
  • [28] Nonclinical safety evaluation of sunitinib (SU11248; SUTENT), a novel multitargeted tyrosine kinase inhibitor for treatment of cancer
    Patyna, S.
    Heward, J. K.
    Evering, W.
    TOXICOLOGIC PATHOLOGY, 2007, 35 (01) : 188 - 188
  • [29] Continuous daily administration of sunitinib malate (SU11248) - A phase II study in patients (PTS) with cytokine-refractory metastatic renal cell carcinoma (MRCC)
    Escudier, Bernard
    Roigas, Jan
    Gillessen, Silke
    Srinivas, Sandhya
    Pisa, Pavel
    Vogelzang, Nicholas
    Fountzilas, George
    Peschel, Christian
    Baum, Charles M.
    De Mulder, Pieter
    ANNALS OF ONCOLOGY, 2006, 17 : 144 - 144
  • [30] Safety and efficacy of sunitinib malate (SU11248) as second-line therapy in metastatic breast cancer (MIBC) patients: preliminary results from a Phase II study
    Miller, K. D.
    Burstein, H. J.
    Elias, A. D.
    Rugo, H. S.
    Cobleigh, M. A.
    Wolff, A. C.
    Eisenberg, R. D.
    Collier, M.
    Adams, B. J.
    Baum, C. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 113 - 114
12345